Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Liuqing Zheng"'
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundDespite significant benefits from targeted therapy in patients with driver mutations, inevitable drug resistance usually occurred in non-small cell lung cancer, highlighting the necessity for sequential treatments to prolong overall surviva
Externí odkaz:
https://doaj.org/article/2dbe0b3373594e9ea3db3f9d330d609e
Autor:
Liuqing Zheng, Jia Wang, Junjie Wang, Ruochen Lei, Hongxiao Jin, Wenxiang Chai, Hongliang Ge, Dingfeng Jin
Publikováno v:
Advances in Polymer Technology, Vol 2024 (2024)
To improve the electrical conductivity, mechanical properties, and antibacterial properties of conventional hydrogels while simplifying their preparation steps for better application in wearable, flexible sensors and biomimetic electronic skins. Poly
Externí odkaz:
https://doaj.org/article/41fcfa71f0e64d1c9c4a01d5c16c5828
Autor:
Weiwei Dong, Huixia Zhao, Shanshan Xiao, Liuqing Zheng, Tongqiang Fan, Li Wang, He Zhang, Yanyan Hu, Jingwen Yang, Tao Wang, Wenhua Xiao
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionTumor-infiltrating myeloid cells (TIMs) are key regulators in tumor progression, but the similarity and distinction of their fundamental properties in pancreatic ductal adenocarcinoma (PDAC) remain elusive.MethodIn this study, we conducte
Externí odkaz:
https://doaj.org/article/def999620aae4a7eb2bc72567604cb11
Autor:
Zhenzhen Hui, Yulin Ren, Dong Zhang, Yulong Chen, Wenwen Yu, Jie Cao, Liang Liu, Tao Wang, Shanshan Xiao, Liuqing Zheng, Yue Pu, Feng Wei, Jian You, Xiubao Ren
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-17 (2023)
Abstract The combination of PD-1 blockade with neoadjuvant chemotherapy (NAC) has achieved unprecedented clinical success in non-small cell lung cancer (NSCLC) compared to NAC alone, but the underlying mechanisms by which PD-1 blockade augments the e
Externí odkaz:
https://doaj.org/article/80b8b7de0c3b43cfb6226552570df70c
Autor:
Yulin Ren, Zhenzhen Hui, Liuqing Zheng, QI Wang, Tao Wang, Shanshan Xiao, Hao Wang, Shaochuan Liu, Xiubao Ren
Publikováno v:
Journal of Clinical Oncology. 40:e21002-e21002
e21002 Background: Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has revolutionized the treatment strategies in multiple cancer types, including NSCLC. Anti-PD1 combined with chemotherapy was superior to chemotherapy alone, but t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a74c433b5caf8b50712b716f6a0dd67
https://doi.org/10.1200/jco.2022.40.16_suppl.e21002
https://doi.org/10.1200/jco.2022.40.16_suppl.e21002
Autor:
Zhenzhen Hui, Jiali Zhang, Yulin Ren, Xiaoling Li, Wenwen Yu, Tao Wang, Liuqing Zheng, Shanshan Xiao, Yu-Long Chen, Feng Wei, Jian You, Xiubao Ren
Publikováno v:
Journal of Clinical Oncology. 40:e20584-e20584
e20584 Background: The combination of immune checkpoint inhibitors (ICIs) with chemotherapy (chemoimmunotherapy) in the neoadjuvant setting have achieved favorable clinical benefits in non-small cell lung cancer (NSCLC), but the underlying molecular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::629bed51bdd3c8435b6d03bdd6e76fb0
https://doi.org/10.1200/jco.2022.40.16_suppl.e20584
https://doi.org/10.1200/jco.2022.40.16_suppl.e20584
Autor:
Jiahui Wang, Qiuru Zhou, Cihui Yan, Zhenzhen Hui, Tao Wang, Liuqing Zheng, Shanshan Xiao, Jian Zhou, Yu Zhao, Zhe Wang, Yulin Ren, Hao Wang, Xiubao Ren
Publikováno v:
Journal of Clinical Oncology. 40:e20566-e20566
e20566 Background: Lung squamous cell carcinoma (LUSC) is one of the most common subtypes of lung cancer which lacks of effective treatments compared to lung adenocarcinoma. The Th1 subset in CD4+ T cells plays an indispensable role in antitumor immu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ddc4b8c48178ec82bfccc8bad391a81
https://doi.org/10.1200/jco.2022.40.16_suppl.e20566
https://doi.org/10.1200/jco.2022.40.16_suppl.e20566